Cargando…
Circulating SPINT1 Is Reduced in a Preeclamptic Cohort with Co-Existing Fetal Growth Restriction
Fetal growth restriction (FGR), when undetected antenatally, is the biggest risk factor for preventable stillbirth. Maternal circulating SPINT1 is reduced in pregnancies, which ultimately deliver small for gestational age (SGA) infants at term (birthweight < 10th centile), compared to appropriate...
Autores principales: | Murphy, Ciara N., Cluver, Catherine A., Walker, Susan P., Keenan, Emerson, Hastie, Roxanne, MacDonald, Teresa M., Hannan, Natalie J., Brownfoot, Fiona C., Cannon, Ping, Tong, Stephen, Kaitu’u-Lino, Tu’uhevaha J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877863/ https://www.ncbi.nlm.nih.gov/pubmed/35207174 http://dx.doi.org/10.3390/jcm11040901 |
Ejemplares similares
-
Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG) secretion from human umbilical vein endothelial cells, primary trophoblast cells and placenta
por: Brownfoot, Fiona C., et al.
Publicado: (2016) -
Circulating SPINT1 is a biomarker of pregnancies with poor placental function and fetal growth restriction
por: Kaitu’u-Lino, Tu’uhevaha J., et al.
Publicado: (2020) -
Elevated Circulating and Placental SPINT2 Is Associated with Placental Dysfunction
por: Murphy, Ciara N., et al.
Publicado: (2021) -
Associations Between Soluble fms‐Like Tyrosine Kinase‐1 and Placental Growth Factor and Disease Severity Among Women With Preterm Eclampsia and Preeclampsia
por: Hastie, Roxanne, et al.
Publicado: (2022) -
Combining metformin and esomeprazole is additive in reducing sFlt-1 secretion and decreasing endothelial dysfunction – implications for treating preeclampsia
por: Kaitu’u-Lino, Tu’uhevaha J., et al.
Publicado: (2018)